Management of transmodiolar and transmacular cochleovestibular schwannomas with and without cochlear implantation

Introduction

Cochleovestibular schwannomas are benign tumors of the eighth cranial nerve with an incidence of approximately 3.4/10⁵ [41]. They usually originate from the vestibular nerve and occur as unilateral, sporadic, nonsyndromic tumors. Bilateral occurrence has been observed in 5–10% of cases associated with neurofibromatosis 2 (NF2) [12]. The usual tumor locations are the internal auditory canal (IAC) and the cerebellopontine angle (CPA) [27]; however, they can also occur as intralabyrinthine schwannomas (ILS) in the terminal branches of the eighth cranial nerve in the inner ear (recently reviewed in [8]).

Hearing loss because of vestibular schwannomas (VS) negatively influences the quality of life and patients with this condition are increasingly interested in hearing rehabilitation with cochlear implantation (CI) [25, 28, 57]. Several case reports, case series and first systematic reviews have illustrated that after surgical removal of sporadic VS or VS associated with NF2, CI can lead to good hearing results, even though not all patients will achieve good speech understanding. The CI may be performed in one stage with tumor removal [3, 45, 50, 57] or in a second surgery [3, 4, 17, 22, 42]. Similar initial results for hearing rehabilitation are available for CI after radiotherapy [9, 28, 31] and with a wait and test and scan strategy [5]. For ILS limited to the inner ear, surprisingly good results with CI with respect to speech understanding have been reported, despite substantial cochlear trauma from the surgical tumor removal [2, 35, 36, 38].

Special subtypes of cochleovestibular schwannomas are located in the inner ear and the IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC), transmacular (TMAC, vestibule and IAC), or translabyrinthine (TLab, intravestibulocochlear with TMOD and TMAC growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas are located in the inner ear and the IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC), transmacular (TMAC, vestibule and IAC), or translabyrinthine (TLab, intravestibulocochlear with TMOD and TMAC growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC), transmacular (TMAC, vestibule and IAC), or translabyrinthine (TLab, intravestibulocochlear with TMOD and TMAC growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC), transmacular (TMAC, vestibule and IAC), or translabyrinthine (TLab, intravestibulocochlear with TMOD and TMAC growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC), transmacular (TMAC, vestibule and IAC), or translabyrinthine (TLab, intravestibulocochlear with TMOD and TMAC growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC), transmacular (TMAC, vestibule and IAC), or translabyrinthine (TLab, intravestibulocochlear with TMOD and TMAC growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC), transmacular (TMAC, vestibule and IAC), or translabyrinthine (TLab, intravestibulocochlear with TMOD and TMAC growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC), transmacular (TMAC, vestibule and IAC), or translabyrinthine (TLab, intravestibulocochlear with TMOD and TMAC growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC), transmacular (TMAC, vestibule and IAC), or translabyrinthine (TLab, intravestibulocochlear with TMOD and TMAC growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC), transmacular (TMAC, vestibule and IAC), or translabyrinthine (TLab, intravestibulocochlear with TMOD and TMAC growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC, transmacular growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC, transmacular growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC, transmacular growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC, transmacular growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC, transmacular growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC, transmacular growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC, transmacular growth into the IAC) (Table 1, Fig. 1). For TMOD and TLab schwannomas in the inner ear and IAC, and sometimes the CPA, i.e., transmodiolar (TMOD, cochlea and IAC, transmacular growth into the IAC) (Table 1, Fig. 1).
Table 1  Classification of cochleovestibular schwannomas with location in the inner ear and the internal auditory canal. (After Kennedy et al. [21] and van Abel et al. [54])

| Classification        | Abbreviation | Cochlea | Vestibule ± SCC | IAC | Middle ear | CPA |
|-----------------------|--------------|---------|-----------------|-----|------------|-----|
| Transmodiolar         | TMOD         | X       | (X)             | X   | –          | –   |
| Transmacular          | TMAC         | –       | X               | –   | –          | –   |
| Translabyrinthine     | TLab         | X       | X               | X   | X          | –   |
| Transotic             | TO           | X       | X               | X   | ±          | –   |
| Involvement of the CPA | + CPA       | ±       | ±               | X   | ±          | X   |

*Extension through the modiolus into the internal auditory canal

†Extension through the macula cribrosa into the internal auditory canal

‡Extension through the modiolus and the macula cribrosa into the internal auditory canal. For intravestibulocochlear tumors and location in the fundus of the IAC, the differentiation to transmacular and transmodiolar extension might be difficult. In our case series no tumor with certain transmodiolar and transmacular (i.e., translabyrinthine) extension was present. Also, this type of tumor extension is not part of the Kennedy et al. classification [21].

IAC internal auditory canal, CPA cerebellopontine angle, SCC semicircular canals

Fig. 1  Schematic drawings of tumor extensions from the inner ear to the internal auditory canal. a Intracochlear schwannoma with transmodiolar extension. b Intravestibulocochlear schwannoma with transmodiolar extension. c Intravestibular schwannoma (+ partially semicircular canals) with transmacular extension. Additional growth into the cerebellopontine angle is also possible (not shown). The facial nerve is located cranially to the cochlear nerve and thus not shown. For simplification, only one vestibular nerve is shown. (Artist: Hans Jörg Schütze, Medical Illustrator, Köln, Germany)

Methods

For this retrospective analysis, patients with a TMOD, TMAC, TLab, or transotic (TO) extension of cochleovestibular schwannoma were included (classification after [21, 54]; Table 1). Patients were selected from a consecutive personal case series of the first author at a tertiary (university) referral center with an interdisciplinary skull base center. The tumors were either primary ILS or classical (intrameatal) schwannomas with secondary invasion of the inner ear and with or without extension into the CPA. Patients were treated between November 2013 and April 2020 and underwent either complete or partial tumor removal with or without CI.

Depending on tumor location and extension, surgery involved a translabyrinthine/transotic approach to the IAC and the CPA or a transmeatal partial or subtotal cochleectomy (for details see Table 2 and “Results”; [2, 33, 35, 36, 38, 39]).

Selection of the type of cochlear implant and electrode array was based on experience and audiological results with previous surgery for ILS [35–38]. In addition, we ascribed to the hypothesis that a perimodiolar electrode array position with close contact of the electrode pads to the spiral ganglion cells in Rosenthal’s canal (here: CI512, CI612, CMD electrodes) with cartilage and fibrosis lateral to the array will lead to reduced spread of the electric field, contributing to a good hearing result after partial and subtotal cochleectomy [56]. Furthermore, the improved magnetic resonance imaging (MRI) compatibility of the magnets in the receiver coil for easier MRI follow-up of the residual tumor was considered, which at that time was mainly present for a limited number of implant models.
(e.g., Synchrony FLEXSOFT, MED-EL, Innsbruck, Austria and Synchrony CMD, MED-EL, later also CI612, Cochlear, Sydney, Australia; Table 2).

Because of the small number and heterogeneity of patients with this rare tumor entity, statistical evaluation was mainly descriptive with a focus on surgical management and adverse events. In patients who underwent CI, the primary endpoint was word recognition in quiet conditions (Freiburger multisyllabic numbers and monosyllables at 65 dB SPL), with masking of the contralateral ear.

Secondary outcome parameters were intraoperative, electrically evoked (via the implant) compound action potentials (eCAP), impedance measures, the presence of a wave V in intraoperative and postoperative electrically evoked brainstem potentials (eABP), and characteristics during implant fitting and programming.

The eCAP were measured with the settings included in the respective manufacturer’s implant programming software (AutoNRT or AutoART). In patients who received a Nucleus implant, a transmodiolar stimulus was used for the eABP [11, 39]. The same stimulus was also used for recording of additional eCAP (AdvancedNRT). In patients with Synchrony implants, individual electrodes or electrode clusters distributed along the array were stimulated.

Results

From a total of 53 consecutive patients with ILS, 9 had tumors with TMOD (n = 6), TMAC (n = 2) or TO (n = 1) extension. Involvement of the CPA (+CPA) was found in three patients (Fig. 2a, 3 and 4). Demographic and baseline data, tumor location, duration of hearing loss before surgery, surgical management, and if appropriate, hearing results with CI are shown in Table 2. All patients were informed of the different management options: 1) wait and test and scan, 2) radiotherapy, 3) complete or incomplete tumor removal, and 4) if possible, hearing rehabilitation with CI. None of the patients chose radiotherapy. Patient 3 was observed until the hearing threshold deteriorated, a hearing aid could not be tolerated because of a reduced uncomfortable loudness threshold, and symptoms of vertigo developed. Patient 5 with NF2 and bilateral deafness was observed until the ipsilateral residual tumor after partial tumor resection had remained stable for some years. The two patients with transmucular tumor extension (8 and 9) showed fluctuating hearing loss, likely because of a secondary endolymphatic cochlear hydrops detected on MRI (Fig. 5a, c). Patient 9 reported increasing dizziness.

Tumor removal was done by previously described surgical techniques either completely (patients 1, 2, 8, and 9; Fig. 2a–d and 5) or incompletely (patients 3–7; Fig. 2f, 3 and 4). Surgical removal of the TO tumor through a translabyrinthine/transotic approach and a lateral petrosectomy (patient 1; Fig. 2a, b) also has been described before [38]. In the two patients with TMAC extension from the vestibule along the superior vestibular nerve into the IAC, tumor removal was done via a translabyrinthine approach, preserving the cochlear nerve and the cochlea (Fig. 5d–h). Incomplete tumor removal was carried out by a transmeatal partial or subtotal cochleoctomy [33, 35, 36, 38] or via push-through or pull-through techniques (also called pipe cleaner, beach towel, or dental floss techniques) [2, 26, 36, 39]. The video (2D and 3D versions, see QR code) shows the transmeatal surgical removal of the intracochlear tumor parts through a partial cochleoctomy and CI in the patient with NF2.

Postoperatively, two patients (patients 7 and 9) reported temporary moderate vertigo. Another patient (patient 3) experienced continuation of a pre-existing vertigo for some weeks after surgery, but the condition continuously improved.
| No. | Age | m/f | Side | Pre-op. 4PTA (dB HL)³/ WRSmax (%) | DHL ⁴ (years) | Tumor localization/extension | Surgery, CI electrode type, Fig. no. | Residual tumor? | Post-op./last WRS₆₅ numbers/monosyllables [%] (months) with CI |
|-----|-----|-----|------|-----------------------------------|---------------|-------------------------------|-------------------------------------|----------------|----------------------------------------------------------|
| 1   | 52  | m   | R    | >110/0                            | 8.75/100      | Transotic + CPA (inner ear, middle ear, IAC, CPA) | Translabyrinthine and transotic approach to IAC and CPA, removal of posterior canal wall, blind sack-like closure of external auditory canal [Fig. 2a,b] | No             | N/A                                                      |
| 2   | 65  | f   | R    | >110/0 (without contralateral CI) | Ca. 28        | Transmodiolar + CPA           | Translabyrinthine and transmeatal transotic approach to IAC and CPA [Fig. 2c,d] | No             | N/A                                                      |
| 3   | 45  | f   | R    | 50/95⁴                            | 13.75/100     | Transmodiolar                 | Partial cochleectomy (extended double cochleostomy) and push-through technique CI: Synchrony, Mi1200 FLEXSOFT [Fig. 2e,f and 7a] | Modiolus/ Fundus of IAC | 50/15 (22)                                               |
| 4   | 48  | f   | R    | >110/0                            | 18.75/100     | Transmodiolar + vestibule; 3 years before: retrosigmoid tumor resection (intrameatal tumor parts) | Partial cochleectomy and tumor removal via pull-through technique + labyrinthectomy CI: CI512 [Fig. 3] | Modiolus | 100/65 (36)                                               |
| 5   | 28  | m   | R    | >110/0                            | >110/0        | Transmodiolar + CPA (secondary invasion of the inner ear), NF2; 4 years before: partial tumor removal via retrosigmoid approach; complete removal of contralateral tumor with deafness | Partial cochleectomy and push-through technique CI: CI512 [Fig. 4a,b and video online via QR code above] | Modiolus, IAC, CPA (large) | 100/85 (24)                                               |
| 6   | 62  | f   | R    | >110/0                            | 20/100        | Transmodiolar + vestibule     | Subtotal cochleectomy and labyrinthectomy CI: CI512 [Fig. 4c,d and 7b] | Modiolus/ Fundus/IAC | 0/0 (24)                                                  |
| 7   | 56  | f   | L    | >110/0                            | 10/100        | Transmodiolar + vestibule     | Subtotal cochleectomy and stapectomy CI: Synchrony CMD [Fig. 4e,f] | Fundus (small) | 100/65 (6)                                                 |
| No. | Age (years) | m/f | Side R/L | 4PTA (dB HL)/WRSmax (%) | DHL (years) | Tumor localization/extension | Surgery | CI electrode type, Fig. no. | Residual tumor? | Post-op./last WRS65 numbers/monosyllables (%) (months) with CI |
|-----|-------------|-----|----------|--------------------------|-------------|-------------------------------|---------|--------------------------|----------------|----------------------------------------------------------|
| 8   | 23          | m   | R        | 47.5/95<sup>e</sup>      | 8.75/100    | <1                           | Transmacular | CI: CI612 Fig. 5          | No             | 100/70 (1)                                               |
| 9   | 24          | f   | R        | 33.75/100<sup>e</sup>    | 11.25/100   | ~0.3                         | Transmacular | Translabyrinthine approach to IAC (CI at second stage) | No             | N/A                                                      |
| N=9 | 45 ± 16     | 3m/6f | 8R/1L | 92±32<sup>f</sup>/37/48   | 37/78±47/44 | 11±11                        | –                     | –                     | –              | 75/50±42/34                                               |

<sup>a</sup>Age at surgery in years
<sup>b</sup>In cases of anacusis (no measurable threshold, >110 dB HL), PTA was set at a dummy code of 120 dB HL (Plontke et al. [32]).
<sup>c</sup>DHL: duration of hearing loss in the side of the tumor

<sup>d</sup>Patient 3: progressive hearing loss over 5 years, WRS<sub>65</sub> 5%, WRS<sub>max</sub> 95% (hearing aid could not be used because of low uncomfortable loudness threshold), vertigo

<sup>e</sup>Patients 8 and 9: fluctuating hearing with secondary cochlear endolymphatic hydrops confirmed with magnetic resonance imaging (MRI) hydrops sequence (patient 8, Fig. 5c); patient 9: additional dizziness

<sup>f</sup>Patient 3: progressive hearing loss over 5 years, WRS<sub>65</sub> 5%, WRS<sub>max</sub> 95% (hearing aid could not be used because of low uncomfortable loudness threshold), vertigo

<sup>i</sup>Patients 8 and 9: fluctuating hearing with secondary cochlear endolymphatic hydrops confirmed with magnetic resonance imaging (MRI) hydrops sequence (patient 8, Fig. 5c); patient 9: additional dizziness

**Table 2** (Continued)

- **WRSmax**: maximum percentage of monosyllables in quiet at 65 dB sound pressure level (dB SPL)
- **CI**: cochlear implant (CI512/612: Nucleus, Cochlear, Sydney, Australia; Synchrony: MED-EL, Innsbruck, Austria)
- **IAC**: internal auditory canal
- **CPA**: cerebellopontine angle
- **N/A**: not available/not applicable

Earlier audiological results for patient 4 were reported as patient 9 in Plontke et al. [36] and for patient 5 in Rahn et al. [39]
Fig. 2  a, b Patient 1 in Table 2. a Magnetic resonance imaging (MRI, axial, T1-w + gadolinium, Gd) showing the transotic tumor with typical gadolinium enhancement in the entire inner ear, IAC and CPA (→), (middle ear extension not shown). b Intraoperative picture showing the facial nerve canal in the mastoid (VII) after lateral petrosectomy and tumor (asterisk) in the IAC + CPA during separation from the facial nerve (→). c, d Patient 2 in Table 2. c MRI (axial, T1-w + Gd) showing the tumor in the cochlea and in the IAC + CPA (→). d Intraoperative view of the fundus of the IAC (→) after combined translabyrinthine and transmeatal-transotic tumor resection. e, f Patient 3 in Table 2. e MRI (axial, T1-w + Gd) showing a transmodiolar ILS with tumor in the second turn of the cochlea and extension into the fundus of the IAC (→). f Intraoperative view after tumor resection from the cochlea with the implant electrode array at the lateral cochlear wall (→). The basal turn was free of tumor. VII facial nerve, Ch. t. chorda tympani, CP cochleariform process; CPA cerebellopontine angle, Gd gadolinium, IAC internal auditory canal, PCW posterior canal wall, TMF tympanomeatal flap, S stapes head, SV scala vestibuli, w weighted. Dotted arrow tumor in cochlea, triangle tumor in vestibule.
Postoperative impedances were unstable in four patients and varied over time. In patient 5, a functional short circuit between two electrodes was found after 6 months. The other patients had stable, homogeneous impedances below 15 kΩ.

The eABP data were available for four patients. In three patients with a Nucleus CIx12 implant, a wave V could be recorded at thresholds of 160–180 current units (cu). In two patients, this correlated with eCAP thresholds that were recorded with the same stimulus. In patient 7, who had the Synchrony CMD implant, no eABP thresholds could be measured.

Postoperative implant programming could be done in all patients based on subjective information through loudness scaling. In 3 patients, 2–4 electrodes had to be deactivated because of discomfort or missing loudness growth. In four patients, relatively high charge levels with an increased pulse width were necessary.

Discussion

This case series presents our experiences with the surgical management of a rare subgroup of cochleovestibular schwannomas, including hearing rehabilitation with cochlear implant in some of these patients. In two patients with TO or TMOD tumor extension including the CPA (patient 1, Fig. 2a, b, and patient 2, Fig. 2c, d), complete tumor removal including the intramodiolar tumor parts had priority for the patients over hearing rehabilitation; thus, CI was not possible. In the two patients (8 and 9) with TMAC tumor growth, the tumor could be completely removed through a translabyrinthine approach with preservation of the cochlear and facial nerves (Fig. 5). Already at the first fitting, the patient with TMAC who underwent CI had reached surprisingly good WRS65 for monosyllables (70% at 65 dB; Table 2, Fig. 6). The five patients with incomplete tumor removal showed a larger variance in WRS65 for monosyllables (minimum 0%, maximum: 100%; Fig. 6). The mean WRS65 for monosyllables after 6 months (52%) was still similar to results for other patients having CI [18, 24, 43], especially compared to patients with implants for single-sided deafness [1, 13, 16, 40, 55]. These results are also similar to or better than those reported in small case series with CI after translabyrinthine resection of classical VS (IAC±CPA) [4, 17, 22, 42, 57]. The WRS65 values, however, were not as good and consistent as those reported for patients with CI after removal of solely intracochlear and intravestibulocochlear schwannomas [35, 36, 56]. There were no serious adverse events.

Intraoperative eCAP and intraoperative and/or postoperative eABP were recorded as secondary outcome parameters. Although for preoperative eABP measurements only the promontory can be stimulated, the intracochlear implant electrode was used as an optimal stimulation site for intraoperative and postoperative recordings. The recordings in patient 7 (CMD electrode) were performed together with the manufacturer. No wave V could be detected in this patient, most likely because of suboptimal stimulation parameters. In all other patients who had a CI, a clear wave V could be recorded. Although all patients (including patient 7) achieved an auditory impression, word recognition ranged from very good (patient 5) to very poor (patient 6). Thus, eABP measurements in principle correlated with implant function, but without a correlation with the expected word recognition. Similar conclusions can be made for the eCAP with preset stimulation parameters, which could be recorded for all electrodes in only one patient.

These observations also correlated with the CI programming. Electrodes had to be deactivated in 3 out of 6 patients, and charge levels had to be set relatively high in 4 out of 6 patients. The fluctuation impedances indicate intracochlear changes, which might explain the deterioration in speech understanding that some of the patients experienced. Whether these changes are the result of
in the IAC and the CPA but not in the inner ear (suggesting secondary ILS or invasive schwannoma). In patients 2, 3, and 4, the origin of the tumor was assumed to be in the IAC. In view of missing earlier MRI images, however, we could not be certain. In addition, a differentiation between TLab and TMOD/TMAC tumor extension is often difficult if the tumor is located in the cochlea and the vestibule (± semicircular canals) and completely fills the fundus of the IAC (e.g., patient 6, Fig. 4c). For surgical management, however, the differentiation between primary versus secondary and TMOD versus TLab does not play a significant role. In cases of tumor extension through the modiolus, hearing rehabilitation with a CI is not compatible with complete tumor removal because spiral ganglion cells in the modiolus are necessary for electrical stimulation. The TMAC tumors represent a special situation, at least with limited extension into the IAC. In these cases, complete tumor removal with preservation of the cochlear nerve in the IAC and very good results for speech understanding with implants seem to be possible (patient 8; Figs. 5 and 6, Table 1).

In addition to surgery, radiotherapy is another treatment option; however, the proximity of the sensory or ganglion cells to the target region needs to be considered. Radiotherapy arrests the tumor growth of classical (IAC±CPA) VS. Initial reports for radiotherapy for VS (no ILS) and CI showed positive results for hearing rehabilitation [5, 9, 31]. Although data for the tolerance doses of the various inner ear structures are sparse, even the frequently recommended cochlear tolerance doses of approximately 5 Gy for single-fraction radiosurgery (SRS) and 35 Gy for fractionated stereotactic radiotherapy (FSRT) are difficult to achieve in any inner ear location, given the required therapeutic doses of approximately 12 Gy in SRS and 54 Gy in FSRT [30]. Irrespective of the radiotherapy technology (SRS via gammaknife or cyberknife, FSRT via linear accelerator), deterioration of existing hearing ability (e.g. cases #3, #8, #9) and restrictions for later rehabilitation with CI are expected.

Even a CI without a therapeutic intervention with respect to the tumor (implant + wait and test and scan) appears to be possible. The first results in patients with intrameatal tumors (± CPA) were promising [5]. In patients with a tumor in the inner ear, however, the implant electrode array would need to be inserted through the tumor, as described by Carlson et al. [6].

After gross total tumor resection (patients 1, 2, 8, and 9 in Table 1), recommendations for MRI follow-up are similar to those for resection of intrameatal (± CPA) tumors. No specific recommendations exist for patients with possible tumor remnants in the modiolus (e.g., after resection of intracochlear, intravestibular, and intravestibulocochlear schwannomas through a subtotal cochleectomy [35, 36]) and/or labyrinthectomy or with only small remnants in the modiolus (e.g., patient 4) or in the fundus of the IAC (e.g., patient 7). Any presence of residual tumor bears the significant risk of growth of the remaining tumor tissue. Even after gross total resection, however, long-term follow-up with MRI is necessary, which patients explicitly need to be told. In a retrospective study, 52 out of 396 (13%) patients with gross total tumor resection experienced a recurrence after a mean of 7.5 years [29]. In contrast, after incomplete but near total resection of intrameatal tumors (± CPA), most patients experienced no or no relevant tumor recurrence. In a series of 1143 patients with translabyrinthine removal of VS evaluated intraoperatively as total (n = 978), near total (n = 140), or subtotal (n = 25) tumor removal, Hahn et al. (2013) reported a rate of revision surgery of 1.2%, i.e., 14 patients with 2 initially receiving total, 5 near total, and 6 subtotal excisions. The authors concluded that most residual tumors disappear spontaneously, probably due to devascularization [15]. Other groups have reported similar observations. The authors noted that the growth rate of residual tumors is less for near total than for subtotal resection and that long-term MRI follow-up (~10 years) is necessary [7, 19, 20, 48]. Imaging follow-up is more difficult for patients with CI. First, the magnet in the receiver coil leads to significant increasing fibrosis or residual tumor tissue could not be determined.

The limitations of the presented observations lie in the small number and heterogeneity of the patient group and the relatively short follow-up period (maximum 36 months). The ILS are rare tumors, and the patients in this case series are a subgroup, representing only 17% (9 out of 53) of our overall cohort of ILS patients. Other authors have reported this subgroup of tumor locations and extensions (TMOD, TMAC, TO, and TLab) in 8% [54], 17% [10], 29% [21], and 42% [44] of their respective case series.

We note that in an individual case, it often cannot be determined whether the tumor is a primary ILS (arising from the inner ear) or started from the IAC with secondary invasion into the inner ear (invasive schwannoma [27]). Initial imaging results frequently already show the tumor in both the inner ear and the fundus of the IAC. An exception in our case series was the patient with NF2 (patient 5). Initial MRI showed the tumor...
Fig. 5  a Transmacular ISL (patient 8 in Table 2). a Pure-tone audiogram showing fluctuating hearing loss (full line: air conduction, dashed line: bone conduction) most likely based on a secondary cochlear hydrops because of the tumor in the vestibule (c). b MRI (coronal, T1-w + Gd) showing the tumor in the right vestibule (triangle), the ampullary ends of the superior and lateral semicircular canals and extension along the superior vestibular nerve into the IAC (→). c MRI with hydrops sequence (3D inversion recovery, 6 h after systemic Gd application) showing a mild cochlear hydrops (→). d Intraoperative view with the tumor (asterisk) in the vestibule and along the superior vestibular nerve towards the fundus of the IAC (→). e–g The tumor (asterisk) is gradually separated from the facial nerve under facial nerve monitoring control. VII facial nerve, Gd gadolinium, I incus body, w weighted
Fig. 6 Results of speech audiometry testing for a multisyllables (numbers) and b monosyllables with the cochlear implant in quiet at 65 dB SPL (WRS65) as a function of time after activation of the speech processor.

Fig. 7 Postoperative MRI (axial, T1-w + Gd) for the two patients with poor hearing outcomes. a Patient 3, at 2 years after removal of the intracochlear tumor parts and CI. Imaging of the IAC and the inner ear was possible by placement of the receiver coil of the Synchrony implant at a distance of approximately 9 cm from the outer ear canal. The tumor part in the fundus of the IAC had increased in size only very slightly by 0.5 mm (compare preoperative MRI: Fig. 2e). b Patient 6, at 2 years and 5 months after removal of the intravestibulocochlear tumor parts and CI. Because of pain and heat development, the magnet of the CI512 model had to be temporarily removed from the patient under local anesthesia. The MRI showed growth of the tumor parts in the IAC by 3.6 mm (compare preoperative MRI: Fig. 4c). There was no tumor recurrence in the inner ear in the two patients. CI cochlear implant, w weighted, → tumor in the IAC.

artefacts, which can impede the evaluation of the inner ear, the IAC, and the CPA. This problem can be counteracted by placement of the receiver coil at a distance of about 9–10 cm from the outer ear canal, which enables imaging of the inner ear and the IAC/CPA despite the implant (Fig. 7a; [46, 49, 51]). Second, the magnetic field can induce significant heat and force, which may lead to pain and magnet dislocation, necessitating revision surgery [14, 23, 47, 49]. Temporary magnet removal or correct securing of a head splint can be used to overcome these problems. For the latter, standard operating procedures are available at our and many other institutions. Recently, magnets have been implemented in some implant models that align with the magnetic field, facilitating MRI follow-up [52, 53].

Conclusion
Cochleovestibular schwannomas with transmodiolar or transmacular extension are very rare and represent a special
entity with respect to management. A therapeutic approach including incomplete and complete tumor removal requires a differentiated assessment considering the therapeutic goal and tumor location and extension. In addition, in these patients, CI can be an option for hearing rehabilitation.

Corresponding address

Prof. Dr. med. S. K. Plontke
Department of Otorhinolaryngology, Head & Neck Surgery, Martin Luther University Halle-Wittenberg, University Medicine Halle-Ernst-Grube-Str. 40, 06120 Halle (Saale), Germany
stefan.plontke@uk-halle.de

Acknowledgments. The surgical videos (2D and 3D) were recorded with a fully digital microscope (ARRISCOPE). We thank Dr. Armin Schneider, Munich Surgical Imaging GmbH (formerly ARRI Medical GmbH), Munich, Germany, for support with cutting and postproduction.

Funding. Open Access funding enabled and organized by Projekt DEAL.

Compliance with ethical guidelines

Conflict of interest. The authors declare the following competing interests:

S.K. Plontke: AudioCure Pharma GmbH, Berlin, Germany (consultant); MED-EL Austria and MED-EL Germany (travel reimbursement for speaking engagement); Oticon Medical, Denmark; Cochlear Ltd., Austria; Bundesministerium für Bildung und Forschung (research projects); BV-HNO e.V.; Merck Serono; Infectopharm; Dr. Willmar Schwabe GmbH & Co. KG, Germany (lecture fees and travel reimbursements); P. Caye-Thomasen: Oticon Medical, Denmark; Cochlear Ltd., Australia; Russia (research projects); T. Rahnne: Oticon Medical, Denmark; Cochlear Ltd., Australia (research projects); MED-EL Austria and MED-EL Germany (travel reimbursement for speaking engagement); G. Götze: MED-EL Austria und MED-EL Germany (research projects); J. T. Rahne: Oticon Medical, Denmark; Cochlear Ltd., Australia (research projects); MED-EL Austria and MED-EL Germany (travel reimbursement for speaking engagement); C. Strauss, S. Kößling, U. Siebolds, D. Vor der Mauer, L. Wagner and L. Frohlich declare that they have no competing interests.

Ethical standards. All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants or their legal representatives for whom identifying information is included in this article.

The supplement containing this article is not sponsored by industry.

Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. In any case, the licence holds in the simple case that the material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Arndt S, Laszig R, Aschendorff A et al (2011) Unilateral deafness and cochlear implantation: audiological diagnostic evaluation and outcomes. HNO 59:437–446
2. Aschendorff A, Arndt S, Laszig R et al (2017) Treatment and auditory rehabilitation of intralabyrinthine schwannoma by means of cochlear implants: English version. HNO 65:46–51
3. Bartindale MR, Tadokoro KS, Kircher ML (2019) Cochlear implantation in sporadic vestibular schwannoma: a systematic literature review. J Neurol Surg B Skull Base 80:632–639
4. Bohr C, Muller S, Hornung J et al (2017) Hearing restoration with cochlear implants after translabyrinthine vestibular schwannoma resection. HNO 65:758–765
5. Borsetto D, Hamilton-Kenny A, Tysome Jr et al (2020) Hearing rehabilitation outcomes in cochlear implant recipients with vestibular schwannoma in observation or radiotherapy groups: a systematic review. Cochlear Implants Int 21:9–17
6. Carlson ML, NeffBA, Sladen DP et al (2016) Cochlear implantation in patients with intracochlear and intralabyrinthine schwannomas. Otol Neurotol 37:647–653
7. Chen Z, Prasad SC, Di Lella F et al (2014) The excitation characteristic of a bipolar stimulus for broadband stimulation in measurements of electrically evoked auditory potentials. Z Med Phys 28:73–77
8. Evans DG, Moran A, King A et al (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93–97
9. Fiszter JB, Holden LK, Reeder RM et al (2012) Auditory abilities after cochlear implantation in adults with unilateral deafness: a pilot study. Otol Neurotol 33:1339–1346
10. Grube G, Wagner J, Hofmann S et al (2017) Prevalence and complications of MRI scans of cochlear implant patients: English version. HNO 65:35–40
11. Hahn CH, Stangerup SE, Caye-Thomasen P (2013) Residual tumor after vestibular schwannoma surgery. J Laryngol Otol 127:568–573
12. Hansen MR, Gantz B, Dunn C (2013) Outcomes after cochlear implantation for patients with single-sided deafness, including those with recalcitrant Meniere’s disease. Otol Neurotol 34:1681–1687
13. Hassepas F, Arndt S, Aschendorff A et al (2016) Cochlear implantation for hearing rehabilitation in single-sided deafness after translabyrinthine vestibular schwannoma surgery. Eur Arch Otorhinolaryngol 273:2373–2383
14. Hoppe UJ, Hocke T, Hart A et al (2019) Maximum preimplantation monosyllabic score as predictor of cochlear implant outcome. HNO. https://doi.org/10.1007/s00106-019-0648-0
15. Jacob JT, Carlson ML, Driscoll CL et al (2016) Volumetric analysis of tumor control following subtotal and near-total resection of vestibular schwannoma. Laryngoscope 126:1877–1882
16. Kasbekar AV, Adan GH, Beacall A et al (2018) Growth patterns of residual tumor in preoperatively growing vestibular schwannomas. J Neurol Surg B Skull Base 79:39–324
17. Kennedy RJ, Shelton C, Salzman KL et al (2004) Intralabyrinthine schwannomas: diagnosis, management, and a new classification system. Otol Neurotol 25:160–167
18. Klenzner T, Glaa M, Volpert S et al (2019) Cochlear implantation in patients with single-sided deafness after the translabyrinthine resection of the vestibular schwannoma-presented at the annual meeting of ADANO 2016 in Berlin. Otol Neurotol 40:e461–e466
19. Leinung M, Loth A, Groger M et al (2020) Cochlear implant magnet dislocation after MRI: surgical management and outcome. Eur Arch Otorhinolaryngol. https://doi.org/10.1007/s00405-020-05826-x
20. Lenarz M, Sonmez H, Joseph G et al (2012) Cochlear implant performance in geriatric patients. Laryngoscope 122:1361–1365
21. Lloyd SRW, King AT, Rutherford SA et al (2017) Hearing optimisation in neurofibromatosis type 2: a systematic review. Clin Otolaryngol 42:1329–1337
22. Ma AK, Patel N (2020) Endoscope-assisted partial cochlcectomy for intracochlear schwannoma with simultaneous cochlear implantation: a case report. Otol Neurotol 41:334–339
23. Merchant SN, Nadol JB (2010) Schwannoma. In: Merchant SN, Nadol JB (eds) Schuknecht’s pathology of the ear. People’s Medical Publishing House PMPH, New Haven, CT, USA, pp 492–508
24. Morcelli C, Boari N, Artico M et al (2020) The emerging role of hearing loss rehabilitation in patients with vestibular schwannomameasured with Gamma Knife radiosurgery: literature review. Neurosurg Rev. https://doi.org/10.1007/s10143-020-01257-8
25. Nakatomi H, Jacob JT, Carlson ML et al (2017) Long-term risk of recurrence and regrowth after gross-total and subtotal resection of sporadic vestibular...
with normal contralateral hearing. Audiol Neurotol 21:286–295
46. Schroeder D, Grupe G, Rademacher G et al (2018) Magnetic resonance imaging artifacts and cochlear implant positioning at 1.5 T in vivo. Biomed Res Int 2018:9163285
47. Shew M, Wichova H, Lin J et al (2019) Magnetic resonance imaging with cochlear implants and auditory brainstem implants: are we truly practicing MRI safety? Laryngoscope 129:482–489
48. Syed MI, Wolf A, Ilan O et al (2017) The behaviour of residual tumour after the intentional incomplete excision of a vestibular schwannoma: is it such a bad thing to leave some behind? Clin Otolaryngol 42:92–97
49. Tam YC, Lee JYW, Gair J et al (2020) Performing MRI scans on cochlear implant and auditory brainstem implant recipients: review of 14.5 years experience. Otol Neurotol 41:e556–e562
50. Thompson NJ, O’connell BP, Brown KD (2019) Translabyrinthine excision of vestibular schwannoma with concurrent cochlear implantation: systematic review. J Neurol Surg B Skull Base 80:187–195
51. Todt I, Rademacher G, Mittmann P et al (2017) Postoperative imaging of the internal auditory canal: visualization of active auditory implants. HNO 65:81–86
52. Todt I, Tittel A, Ernst A et al (2017) Pain free 3 T MRI scans in cochlear Implantees. Otol Neurotol 38:e401–e404
53. Tysome JR, Tam YC, Patterson I et al (2019) Assessment of a novel 3 T MRI compatible cochlear implant magnet: torque, forces, demagnetization, and imaging. Otol Neurotol 40:e966–e974
54. Van Abel KM, Carlson ML, Link MJ et al (2013) Primary inner ear schwannomas: a case series and systematic review of the literature. Laryngoscope 123:1957–1966
55. Vlastarakos PV, Nazos K, Tavoulari EF et al (2014) Cochlear implantation for single-sided deafness: the outcomes. An evidence-based approach. Eur Arch Otorhinolaryngol 271:2119–2126
56. Wagner L, Plontke SK, Frohlich L et al (2020) Reduced spread of electric field after surgical removal of intracochlear schwannoma and cochlear implantation. Otol Neurotol (corrected proofs, in press)
57. West N, Sass H, Caye-Thomasen P (2020) Sporadic and NF2-associated vestibular schwannoma surgery and simultaneous cochlear implantation: a comparative systematic review. Eur Arch Otorhinolaryngol 277:333–342